Curated News
By: NewsRamp Editorial Staff
June 26, 2025
Quantum BioPharma's Unbuzzd Secures $5M to Expand Hangover Relief Beverage
TLDR
- Quantum BioPharma's portfolio company Unbuzzd Wellness Inc. secures up to $5 million in funding, offering investors a stake in a potential future IPO and a unique beverage innovation.
- Unbuzzd Wellness Inc., under Quantum BioPharma, plans to use Regulation D 506(c) offering funds to expand its market reach, leveraging partnerships with MZ Digital and Dealmaker.
- Unbuzzd Wellness Inc.'s beverage aims to reduce hangover symptoms, contributing to healthier lifestyles and potentially decreasing alcohol-related harms, aligning with Quantum BioPharma's focus on metabolic disorders.
- Quantum BioPharma's Unbuzzd, a hangover-reducing beverage, backed by industry veterans, marks a novel approach to alcohol metabolism, blending biotech innovation with consumer wellness.
Impact - Why it Matters
This news is pivotal for investors and consumers alike, as it highlights Quantum BioPharma's innovative approach to tackling alcohol-related disorders and its strategic moves towards expanding market reach and potential IPO. The development of products like unbuzzd(TM) and Lucid-MS represents a significant advancement in biotech solutions for health and wellness, offering new avenues for treatment and prevention of conditions like multiple sclerosis and hangovers. The partnership and funding initiative underscore the growing interest and investment in biotech innovations that address real-world health challenges.
Summary
Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company at the forefront of biotech innovation, has announced a significant partnership involving its portfolio company, Unbuzzd Wellness Inc. Unbuzzd, known for its innovative beverage unbuzzd(TM) aimed at accelerating alcohol metabolism and mitigating hangover symptoms, has teamed up with MZ Digital and Dealmaker to secure up to $5 million through a Regulation D 506(c) offering. This strategic move, spearheaded by CEO John Duffy, a former Coca-Cola executive, and advised by Gerry David, ex-CEO of Celsius Holdings, is poised to expand Unbuzzd's direct-to-consumer, retail, and distributor channels, setting the stage for a potential future IPO.
Quantum BioPharma's commitment to addressing challenging neurodegenerative and metabolic disorders, including alcohol misuse, is further highlighted through its subsidiary, Lucid Psycheceuticals Inc., which is advancing the development of Lucid-MS, a promising compound for multiple sclerosis. Additionally, Quantum BioPharma's strategic investments and royalty agreements, such as those with Celly Nutrition Corp., underscore its innovative approach to biotech solutions and its potential for significant impact in the pharmaceutical and wellness industries. For more details, visit https://ibn.fm/t7BCB.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Unbuzzd Secures $5M to Expand Hangover Relief Beverage
